ClinicalTrials.gg
RecruitingNCT07491315MAPEMCARUpdated Jun 8, 2026

Is Post-exertional Symptom Exacerbation Specific to Patients With Myalgic Encephalomyelitis / Chronic Fatigue Syndrome? A Study Comparing Patients With Myalgic Encephalomyelitis / Chronic Fatigue Syndrome and Patients With Cardiac Diseases Who Underwent an Exercise Test.

An interventional study of Exercise test on ergocycle and Near Infrared Spectroscopy (NIRS) in Fatigue Syndrome, Chronic and Cardiovascular Diseases, sponsored by Hôpital Européen Marseille. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Hôpital Européen Marseille · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jun 2025, registered Mar 2026).
  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) is a disease characterized by persistent and unexplained fatigue associated with diffuse pain, sleep disorders, neurocognitive and autonomic symptoms, musculoskeletal manifestations and digestive symptoms. A central feature of this disease is post-exertional symptom exacerbation, also referred to as post-exertional malaise, defined as the worsening or the appearance of symptoms after physical or mental exertion, sometimes even minimal.

Several studies have described post-exertional malaise in populations of patients with ME/CFS following a standardized exercise test performed over one or two consecutive days. These studies confirmed the presence of post-exertional malaise in ME/CFS patients compared with healthy controls or patients with multiple sclerosis.

However, no data are available evaluating the impact of an exercise test on symptoms in patients referred to cardiology for this examination. Patients with cardiac diseases may also present symptoms such as fatigue, dyspnea or exercise intolerance.

This study aims to compare post-exertional symptoms in two populations: patients with ME/CFS and patients with cardiac diseases undergoing an exercise test as part of routine clinical evaluation. The study also aims to measure variations in muscle oxyhemoglobin and deoxyhemoglobin concentrations before, during and after exercise using Near Infrared Spectroscopy (NIRS).

02

Conditions studied

  • Fatigue Syndrome, Chronic
  • Cardiovascular Diseases
03

In context

Fatigue Syndrome, Chronic

265 studies on the registry are indexed under Fatigue Syndrome, Chronic; 63 are open to participants now.

This study's planned enrollment of 80 is above the median of 60 across 179 interventional studies indexed under Fatigue Syndrome, Chronic.

Browse Fatigue Syndrome, Chronic studies →

Lead sponsor

Hôpital Européen Marseille is the lead sponsor of 30 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18 years
  • For patients with Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS): Clinical diagnosis of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome according to the International Consensus Criteria (ICC) 2011.
  • For patients with cardiac diseases : patients referred for an exercise test in the cardiology department for one of the following indications: palpitations, hypertension, exertional dyspnea, chest pain, cornoray artery disease and presence of moderate to severe fatigue defined as a Numerical Rating Scale (NRS) > 3/10 during the last 8 days and no diagnosis of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome.
  • Ability to use a computer or digital device required to complete online questionnaires.
  • Having given free and informed written consent

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding woman
  • Persons deprived of their liberty by a judicial or administrative decision.
  • Persons who are subject to a legal protection measure or who are unable to express their consent.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Other
    Fatigue Syndrome, Chronic

    Other: Exercise test on ergocycle · Other: Near Infrared Spectroscopy (NIRS)

  • Other
    Cardiovascular diseases

    Other: Exercise test on ergocycle · Other: Near Infrared Spectroscopy (NIRS)

Interventions

  • OtherExercise test on ergocycle

    Participants will undergo a standardized exercise test performed on a cycle ergometer. Symptoms will be assessed using questionnaires before the test and during the 7 days following the exercise test.

  • OtherNear Infrared Spectroscopy (NIRS)

    Muscle oxygenation will be monitored using Near Infrared Spectroscopy (NIRS) before, during and after exercise

06

What researchers measure

Primary outcomes

  1. Time to onset of symptoms after completion of the exercise test on an ergocycle in both groups.

    Type of symptoms reported by participants after the exercise test.

    Time frame: From immediately after the exercise test up to Day 7.

Secondary outcomes

  1. Symptoms observed during the 7 days following the exercise test in both groups

    Type of symptoms reported by participants after the exercise test.

    Time frame: From immediately after the exercise test up to Day 7.

  2. Duration of symptoms after the exercise test in both groups.

    Type of symptoms reported by participants after the exercise test.

    Time frame: From immediately after the exercise test up to Day 7.

  3. Intensity of post-exercise symptoms measured in both groups.

    Type of symptoms reported by participants after the exercise test.

    Time frame: From immediately after the exercise test up to Day 7.

  4. Characterization of symptoms experienced before the exercise test in both groups.

    Baseline symptom characterization using the DePaul Symptom Questionnaire - Post-Exertional Malaise (DSQ-PEM). The DSQ-PEM evaluates the frequency and severity of post-exertional malaise symptoms. A frequency score and a severity score ≥ 2 for at least one of items 1-5 are indicative of post-exertional malaise. For diagnostic classification, either item 7 or item 8 must be positive, and item 9 must indicate a duration of symptoms greater than 14 hours. Higher frequency and severity scores indicate greater symptom burden.

    Time frame: Day 0 (prior to the exercise test).

  5. Variations in oxyhemoglobin and deoxyhemoglobin concentrations measured by Near Infrared Spectroscopy (NIRS) at the muscular level before, during and after exercise.

    Measurement of changes in oxyhaemoglobin and deoxyhaemoglobin concentrations in muscle tissue using Near-Infrared Spectroscopy (NIRS).

    Time frame: Before, during, and up to 10 minutes after the exercise test.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 73 non-industry interventional studies with no phase under Fatigue Syndrome, Chronic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 18 months is below that.

Counting every sponsor, half of 78 studies reached it within 23 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Mar 24, 2026
StartActual
Jun 24, 2025
Primary completionEst.
Dec 24, 2026
CompletionEst.
Dec 24, 2026
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07491315
Lead sponsor
Hôpital Européen Marseille
Responsible party
Sponsor
First posted
Mar 24, 2026
Start date
Jun 24, 2025
Primary completion
Dec 24, 2026 (estimated)
Completion
Dec 24, 2026 (estimated)
Last update
Jun 8, 2026

Study contacts

Myriam BENNANI
Contact
m.bennani@hopital-europeen.fr
0413428351

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion